BioNTech's Financial Performance in Q4 2024

BioNTech SE has recently disclosed its financial outcomes for the fourth quarter of the fiscal year 2024, revealing a substantial 24.4% year-over-year decrease in total revenue, settling at €1.2 billion. Despite this downturn, the figures have surpassed analysts' forecasts. The company also reported a net profit of €259.5 million, a decline from the €457.9 million net profit recorded in the corresponding period of 2023. Furthermore, the diluted earnings per share (EPS) stood at €1.08, a drop from the EPS of €1.88 reported a year earlier.

Full Fiscal Year Overview

For the entire fiscal year 2024, BioNTech announced total revenues of €2.7 billion, a decrease from the €3.8 billion achieved in 2023. The diluted loss per share was reported at €2.77, contrasting with the €3.83 earnings per share in the previous year.

CEO's Statement on Progress

"In 2024, we made significant progress towards our vision through important oncology pipeline advancements, including the initiation of global Phase 3 clinical trials for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 and key data updates from our mRNA cancer immunotherapy programs," stated CEO Ugur Sahin. Following the earnings report, BioNTech's shares in the United States experienced a 1.93% decline in premarket trading.